ERBB2 and neoplasm: Biomarkers, in particular MSI, PD-L1, tumor mutation burden, Epstein-Barr virus, and human epidermal growth factor receptor 2 (HER2) are becoming an increasingly important factors in systemic therapeutic methods and in determining which patient groups are most likely to benefit from immunotherapy and targeted therapies (Joshi and Badgwell, 2021).